Transcranial magnetic stimulation

Published 2014-04

Products and services using Transcranial magnetic stimulation are generally available around 2022

Verdict

hitTwo blind graders agree (D7, rule D37). The auditor agent confirmed it (D11).

Grader A: hit
Grader B: hit
agrees with A, without seeing its verdict
Audit: confirmed
in the fixed audit sample (D11)
Published: hit

Grader A: hit

FDA-cleared NeuroStar TMS for major depression (classified 2011, first cleared 2008) and Brainsway deep TMS (2013) were in routine clinical sale before the poster.

Test: D37 Horizons: TMS devices or treatments available to ordinary patients or clinics by 2024 (earlier counts).

Transcranial magnetic stimulation (Wikipedia) (2011-07): FDA classified NeuroStar TMS for treatment of MDD (July 2011); Brainsway Deep TMS cleared January 2013.

Grader B: hit

Neuronetics' NeuroStar TMS was FDA-cleared for depression in 2008 and sold to clinics; TMS therapy was widely reimbursed by 2014. Available long before the mark.

Test: TMS devices or treatments could be bought by clinics or patients by 2024 (earlier counts).

FDA 510(k) K083538 NeuroStar TMS Therapy System (2008-12-16): FDA clearance of a commercial TMS system for major depressive disorder.

In our research

CortexTranscranial Magnetic Stimulation Systems

All captured fields

id: hz-2014-013
category: Neurotechnology and cognitive technologies
kind: technology
target year: 2022
placed year: 2022
milestones: {"scientifically_viable":2014,"mainstream":2019,"financially_viable":2022}
confidence: high
note: Numbered dot (mainstream point) at 2019.3, between the 2019 and 2020 lines, nearer 2019 (read as 2019). Bar from 2013.8 to 2022.4: scientifically viable ~2014, financially viable ~2022. The bar reaches the inner edge of the grid (~2014), so scientific viability may be at or before the chart start. Sub-area: Neural interfaces.